07/10/2024 / By Ethan Huff
The market for the popular weight loss drug Wegovy (semaglutide) is expanding after Novo Nordisk, the Denmark-based pharmaceutical giant that manufactures it, issued new claims that the controversial pharmaceutical injection supposedly also helps to prevent heart attack, stroke and early death.
Conveniently for the company, Wegovy allegedly works against a variety of cardiovascular problems that just so happen to be skyrocketing in society ever since the release of Wuhan coronavirus (COVID-19) vaccines under the Trump administration’s Operation Warp Speed military program.
According to Novo Nordisk, taking Wegovy, a drug made from reptilian venom peptides, along with “a reduced-calorie diet and increased physical activity” can “lower the risk of major cardiovascular events.”
“Adults living with overweight or obesity and known heart disease are at an increased risk for another major cardiovascular event,” the company claims.
(Related: Weight loss drug Ozempic, also made by Novo Nordisk, is linked to serious health problems such as vomiting: “I wish I never touched it.”)
Novo Nordisk would not have been able to expand the list of uses for Wegovy were it not for the U.S. Food and Drug Administration (FDA), which gave the company the green light to start pushing the drug for heart-related conditions.
The FDA functions as a rubber stamp for the drug industry to continue delivering “blockbuster” new drugs to the market every time it needs another new profit stream. Nowadays, though, Big Pharma seems to be simply repurposing old drugs for new conditions in order to generate fresh profit streams.
Wegovy is particularly controversial because just like Ozempic, which is the same drug under a different name, it causes sagging and aging of facial skin, a condition more popularly known as “Ozempic face.”
People who develop Ozempic face are now being told by the medical establishment that they could require “facial fillers” and other “lifestyle modifications” to get their old look back.
Medical News Today‘s Oladimeji Equmi wrote a piece medically reviewed by Ami Patel PharmD, BCPS that describes in further detail the nature of Ozempic face, which causes users to develop “a hollowed-out appearance” on their face as well as “increased signs of aging such as more lines and wrinkles.”
Because it targets fat, Ozempic and Wegovy also eat away at the elastin in skin that creates a youthful appearance, leaving behind loose and saggy skin.
Dr. Paul Jarrod Frank, a cosmetic and celebrity dermatologist, is credited with coming up with the term Ozempic face after he started treating many patients who developed it after taking the drug.
“Facial fat serves a protective function and affects facial aesthetics and elasticity,” Equmi writes. “Weight loss can cause dermatological changes and shrinking because the fat that stretches and cushions the skin is no longer in place.”
“The skin of the face also loses its ability to retract after an episode of rapid weight loss due to reduced levels of elastin and collagen, which are essential for structural integrity.”
On its website for Wegovy, Novo Nordisk explains that there are other “serious side effects” caused by the drug that include “possible thyroid tumors, including cancer.”
“Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath,” the company urges. “These may be symptoms of thyroid cancer.”
Studies on rodents found that Wegovy and Ozempic caused the animals to get sick with thyroid cancer, which is why Novo Nordisk warns in small print that people with a family history of thyroid cancer or an endocrine system disorder called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should avoid taking it.
Other serious side effects associated with Wegovy and Ozempic include:
– Inflammation of the pancreas (pancreatitis)
– Gallbladder problems including gallstones
– Increased risk of low blood sugar (hypoglycemia)
– Kidney problems (kidney failure)
– Serious allergic reactions
– Vision problems in people with type 2 diabetes
– Increased heart rate
– Depression and suicidal thoughts
The most common side effects associated with Wegovy include nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headaches, tiredness (fatigue), upset stomach, dizziness, bloating, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, runny nose and sore throat.
There is a new kid on the block called Zepbound (tirzepatide) from Eli Lilly that supposedly works better than Ozempic and Wegovy at cutting fat, but at what cost?
First approved back in late 2023, Zepbound is part of a new class of drugs called GLP-1s that Big Pharma is pushing to make fat people skinny. One can only imagine what its side effects might be.
Like semaglutide, tirzepatide and other GLP-1 drugs mimic a hormone in the body that helps to reduce hunger and appetite. It also imitates a second hormone called GIP that is believed to break down sugar and fat.
Consumers need to beware of all of these drugs because not only are they dangerous but because of their popularity they are also being “pirated,” meaning there are many counterfeit imitators out there labeled as these drugs when they are actually something else.
A recently published study further found that Ozempic and Wegovy increase the risk of a rare form of blindness called nonarteritic anterior ischemic optic neuropathy, also known as NAION.
The latest news about dangerous pharmaceutical medications like Wegovy can be found at BadMedicine.news.
Sources for this article include:
Tagged Under:
Big Pharma, Censored Science, chemical violence, COVID, covid-19, death, drug, eli lilly, Gila monster, heart attack, incretin mimetics, ingredients, Novo Nordisk, pharma fraud, reptile, slender, stroke, suppressed, vaccination, venom, Wegovy, weight loss, Zepbound
This article may contain statements that reflect the opinion of the author
HeartDisease.News is a fact-based public education website published by Heart Disease News Features, LLC.
All content copyright © 2018 by Heart Disease News Features, LLC.
Contact Us with Tips or Corrections
All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners.